The system, the result of years of research and development in close liaison with peptide scientists around the world, offers the potential for far-reaching, new pharmaceutical peptide discoveries.
Following the installation of the first production Peptide-Builder at the UEA, Chief Scientific Officer, Dr Manuel Nuño, led a comprehensive two-day hands-on training session with Professor Mark Searcey and Dr Andrew Beekman’s research teams.
During the session, the groups successfully synthesised 16-mer, 23-mer and 35-mer peptides, demonstrating the Peptide-Builder’s reliability, intuitive operation, and the power of real-time monitoring to deliver valuable insights into reaction performance and optimisation.
“Seeing the first production Peptide-Builder in operation at UEA is a proud moment for the Vapourtec team,” said Dr Nuño. “It represents years of development and close collaboration with peptide scientists”.
Dr Andrew Beekman commented; ““We are very excited to begin using the Peptide-Builder in our research. The ability to monitor synthesis in real time, obtain detailed reaction data and queue up to 16 peptides for automated synthesis will be a great addition to our peptide synthesis workflow.”
Professor Searcey’s group will now integrate the Peptide-Builder into their ongoing investigations of novel peptides that target DNA and protein–protein interactions - research that could help unlock new anticancer, antimicrobial, and anti-inflammatory therapeutics.
Dr Nuño concluded: “We’re excited to support UEA as they begin this next phase of peptide synthesis research.”
